196 results about "Stage melanoma" patented technology

The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fcγ receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fcγ receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.

The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5T4 (Trophoblast glycoprotein, TPBG), Survivin (Baculoviral TAP repeat-containing protein 5; BIRC5), NY-ESO-1 (New York esophageal squamous cell carcinoma 1, CTAG1B), MAGE-C1 (Melanoma antigen family C1), MAGE-C2 (Melanoma antigen family C2), and MUC1 (Mucin 1). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (NSCLC), and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the composition and/or the vaccine.

The invention relates to the field of medicines, in particular to an angiogenesis inhibitor for inhibiting several matrix metal protein enzyme and inhibiting the transfer of the vascular endothelial cell, which can be applied to preparation and treatment of entity tumor and rheumatoid arthritis. The polypeptide comprises a polypeptide I, polypeptide II, polypeptide III and polypeptide IV (Seq NO.1, Seq NO.2, Seq NO.3, Seq NO.4); The polypeptide can be used for treating entity tumor and rheumatoid arthritis. The four angiogenesis inhibitors can be applied to preparation of medicine for treating tumor, and is characterized in that: the tumor is derived from primary of neck, brain, thyroid gland, esophagus, pancreas, lung, liver, stomach, mammary gland, kidney, colon or rectum, ovary, cervix, uterus, prostate, bladder and testis or secondary cancer, melanoma, hemangioma and sarcoma.

The invention relates to the field of medicines, and in particular relates to an inhibitor of angiogenesis capable of inhibiting matrix metallo-proteinase and migration of vascular endothelial cells. The inhibitor can be used for preventing and treating solid tumor and rheumatoid arthritis. The polypeptide specifically means polypeptide I, polypeptide II, polypeptide III and polypeptide IV (with reference to SeqNO.1, SeqNO.2, SeqNO.3 and SeqNO.4). The polypeptide can be used for treating solid tumor and rheumatoid arthritis. The four inhibitors of angiogenesis can be applied to preparing medicines for treating tumor. The polypeptide is characterized in that tumor is originated from essential or subsequent cancers, melanoma, hemangioma and sarcoma of heat and neck, brain, thyroid, esophagus, pancreas, lung, liver, stomach, breast, kidney, gall bladder, colon or rectum, ovary, cervix uterus, uterus, prostate, bladder and testis.

The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1-negative melanoma and (ii) administering to the patient a combination of an anti-PD-1 antibody or an antigen-binding portion thereof and an anti-CTLA-4 antibody or an antigen-binding portion thereof. The methods of the invention can extend progression-free survival for over 8 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.

The invention belongs to the technical field of drugs, and particularly relates to aminopeptidase N inhibitor, a preparation method and application to tumor resistance. The technical scheme includes that the aminopeptidase N inhibitor is chemically named as (S)-4-methyl-2-(3-naphthyl-1-ylmethyl-ureido)-valeryl group hydroxylamine. The constitutional formula (I) of the aminopeptidase N inhibitor is shown here. The pharmacodynamic effect of the aminopeptidase N inhibitor is evaluated by in-vitro APN (adiponectin) inhibitory experiments, in-vitro resistance to tumor cell invasion, antiangiogenesis and mouse in-vivo resistance to melanoma manual transfer and antiangiogenesis experiments.

The present invention provides novel compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

The invention discloses a complete humanized antibody which is selected from humanized high-capacity phage antibody library and is high-affinity-combined with phosphatidylinositol proteoglycan 3. The invention includes a selection method of the antibody, an antibody coding sequence and corresponding amino acid residue sequence, and especially includes three CDR-zone sequences respectively at a heavy chain and a light chain, combination characters of an antigen and the construction method of the complete antibody. The antibody is a complete humanized antibody, is used for treatment in human body, is low in immunogenicity, is less in toxic and side effects, and has a potential value of treating liver cancer and melanin tumor.

The invention provides a proteolytic targeting chimeric body, a prodrug molecule for improving oral bioavailability of the proteolytic targeting chimeric body and application thereof. According to thetechnical scheme, a novel PROTAC degradation agent compound is developed on the basis of a ribociclib derivative and a CRBN ligand. Small molecules can effectively degrade CDK2/4/6 and compounds thereof in malignant melanoma at the same time; the cell cycle can be quickly reset, and apoptosis of various cancer cells, especially melanoma cells, can be induced. A mechanism should be explained as that CDK 2/4/6 deficiency may lead to synthetic lethal effects of malignant melanoma in the presence of a compound. The results show that the combination of CDK2/4/6 is expected to become a kinase target for treating solid tumors. In addition, the invention also develops a prodrug with high oral bioavailability for the first time, and is convenient for oral administration in animal tests. A universal solution is provided for oral administration of PROTAC molecules with CRBN ligands.

The invention discloses the preparation and application of a lentiviral vector expressing a codon-optimized Anti-MART-1 TCR gene with improved safety. The safety of the vector is achieved by replacing the WPRE element of the original lentiviral vector with an OPRE element, the sequence of which is shown in SEQ ID No.: 1, and inserting a codon-optimized Anti-MART at the multi-cloning site of the vector -1 TCR nucleotide sequence, the sequence is shown in SEQ ID No.:2. Compared with WPRE, the OPRE element had no significant effect on the transfection efficiency and packaging titer of the lentivirus; the codon-optimized Anti-MART-1 TCR gene had 79% homology with the wild-type gene, and was found in T cell genes. Modification can significantly increase the expression level of Anti-MART-1 TCR; after co-culture of T cells expressing Anti-MART-1 TCR with melanoma cell lines, the secretion level of IFN-γ is also significantly increased; The cells also significantly prolonged the survival of tumor-bearing mice implanted with melanoma tumors and inhibited the growth of melanoma tumors. The transformed pRRLSIN.cPPT.MSCV‑CoAnti‑MART‑1/GFP.OPRE vector can be used for the construction of TCR‑T cells in cell therapy and other purposes.

The invention discloses a peripheral blood TCR marker of melanoma as well as a detection kit and application of the peripheral blood TCR marker. The marker comprises at least one of proteins of whichthe sequences are shown as SEQ ID NO. 1-100. The sequence is based on a high-throughput sequencing method; only a small amount of peripheral blood needs to be collected; RNA (Ribonucleic Acid) is extracted, a sample is treated to establish an immune map library, high-throughput sequencing and TCR data analysis are carried out, a characteristic TCR sequence in peripheral blood of melanoma is determined, and then a test result of a sample to be tested is compared with the characteristic TCR sequence so as to determine whether the melanoma exists or not. According to the kit, a huge number of melanoma specific TCR sequences can be compared at the same time, and compared with single detection of one or more markers, the kit has higher specificity and accuracy, and the diagnosis efficiency is improved.

The invention provides an ACE (angiotensin converting enzyme) inhibition peptide with nutrition repairing and cell function activation and a preparation method. The peptide is a small-molecule peptidewhich is separated and extracted from black foods. It finds that the peptide self is an ACR (anti-hypertension) inhibitor, and experiment shows that the peptide has an activation function on TIDCs (tumorindiltrating dendritic cells) induced by melanoma cells, and has a repairing function on A549 cell injury caused by hydrogen peroxide; a medicine made of the small-molecule peptide has the characteristics of being remarkable in clinical effect and small in toxic and side effect; and the preparation method of the food small-molecule peptide extracted by the invention is simple and practical.

A modified melanoma cell line capable of quantification of the effects of MEK inhibitors and CDK4/6 inhibitors in a quantitative, temporal and non-invasive manner both in vitro and in vivo.

The present invention comprises a new class of compounds capable of modulating the activity of Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula (I) wherein each of A¹, A², A³, A⁴, A⁵, A⁶, A⁷, A⁸, A⁹, bond B, X, rings Z¹ and Z², R¹ and R³ are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

The invention discloses a culture method of high-memory phenotype tumor-infiltrating T lymphocytes. The culture method comprises the following steps of aseptically cutting tumor tissues and putting the tumor tissues into a culture solution, mechanically cutting and digesting tumor bodies under an aseptic cold chain condition to obtain a single-cell suspension, separating and extracting the tumor-infiltrating T lymphocytes, and obtaining the high-memory phenotype tumor-infiltrating T lymphocytes by adding the tumor-infiltrating T lymphocytes into a culture medium containing a separation induction culture solution for in-vitro amplification and induced differentiation, and culturing for 7-21 days, wherein the separation induction culture solution is a culture medium containing IL-2, IL-7 and IL-15 with the concentrations of 10ng/ml, 10ng/ml and 20ng/ml respectively. According to the method, the TIL cells are subjected to in-vitro amplification and induced differentiation by separating and inducing the culture solution, the high-memory phenotype TILs with efficient proliferation activity and strong tumor killing ability are obtained to the maximum extent, the method is simple and efficient, the proportion of the memory phenotype T lymphocytes is high, and the TILs can be used for treating advanced malignant melanoma.

Compositions and methods for determining endometrial receptivity to embryo implantation and for detecting and treating castration-recurrent prostate cancer are provided. The methods comprise measuring the level of melanoma antigen gene protein-11 (MAGE-11, also referred to as MAGE-Al 1) in an endometrial or prostate tissue sample. The level of MAGE-11 protein or mRNA can be correlated to endometrial receptivity to embryo implantation in a female human or nonhuman primate, or to the presence of castration-recurrent prostate cancer in a male patient in need thereof. Methods are described whereby MAGE-11 may serve as a target for vaccine development in the treatment of castration-recurrent prostate cancer. Methods for monitoring endometrial maturation, for diagnosing infertility, and for in vitro fertilization in a female human or nonhuman primate are also provided. Compositions of the invention include antibodies that specifically bind MAGE-11 and oligonucleotide primers useful for detecting MAGE-11 mRNA, as well as kits containing such antibodies or primers.

The invention relates to an acylated derivative of resiquimod, a preparation method and the application thereof. The general formula of the acylated derivative of resiquimod is as shown in the specification, wherein R1 is selected from one of benzoyl, acetyl, formyl, phenylacetyl and hydrogen; and R2 is selected from one of benzoyl, formyl, hydrogen and acetyl. The acylated derivative of resiquimod provided by the invention has good activity application for oral cancer cells and melanoma cells, and has good clinic application values. The acylated derivative of resiquimod has obvious effects inthe application for curing oral cancer and melanoma.